DOCSLIB.ORG

790 Antineoplastics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
790 Antineoplastics 790 Antineoplastics Viessia; Vinilex; Neth.: Navelbine; Norw.: Navelbine; NZ: Navelbine; long as there is no evidence of progressive disease or unaccepta- Philipp.: Navelbine; Vinotel; Pol.: Navelbine; Navirel; Port.: Navelbine; ble toxicity. Vinorel; Rus.: Maverex (Маверекс); Navelbine (Навельбин); S.Afr.: Navel- bine; Singapore: Navelbine; Spain: Navelbine; Swed.: Navelbine; Switz.: Vorinostat is also under investigation for the treatment of multi- O Navelbine; Thai.: Navelbine; Vinelbine; Turk.: Navelbine; UK: Navelbine; ple myeloma and mesothelioma. H CO USA: Navelbine. 3 ◊ References. CH3 OO 1. O’Connor OA. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoy- H Vorinostat (USAN, rINN) lanilide hydroxamic acid in patients with advanced hematologic O malignancies. J Clin Oncol 2006; 24: 166–73. SAHA; Suberoylanilide Hydroxamic Acid; Vorinostatum. N-Hy- 2. Krug LM, et al. Potential role of histone deacetylase inhibitors O droxy-N′-phenyl octanediamide. in mesothelioma: clinical experience with suberoylanilide hy- H droxamic acid. Clin Lung Cancer 2006; 7: 257–61. OH O Вориностат 3. Richon VM. Cancer biology: mechanism of antitumour action of CH3 C H N O = 264.3. vorinostat (suberoylanilide hydroxamic acid), a novel histone 14 20 2 3 OH H CAS — 149647-78-9. deacetylase inhibitor. Br J Cancer 2006; 95 (suppl): S2–S6. O 4. O’Connor OA. Clinical experience with the novel histone OH deacetylase inhibitor vorinostat (suberoylanilide hydroxamic ac- O H id) in patients with relapsed lymphoma. Br J Cancer 2006; 95 H (suppl): S7–S12. HN O N 5. Duvic M, Zhang C. Clinical and laboratory experience of vori- CH3 O nostat (suberoylanilide hydroxamic acid) in the treatment of cu- taneous T-cell lymphoma. Br J Cancer 2006; 95 (suppl): S13–S19. Description. Zinostatin is an antineoplastic antibiotic obtained HN 6. Anonymous. Vorinostat (Zolinza) for cutaneous T-Cell lympho- from Streptomyces carzinostaticus. ma. Med Lett Drugs Ther 2007; 49: 23–4. OH Preparations Pharmacopoeias. Jpn includes zinostatin stimalamer. Proprietary Preparations (details are given in Part 3) Profile Adverse Effects, Treatment, and Precautions USA: Zolinza. Zinostatin is an antibiotic with antineoplastic activity and has For general discussions see Antineoplastics, p.635, p.639, and p.641. been used in the treatment of malignant neoplasms. The most common adverse effects of vorinostat are gastrointes- Zinostatin stimalamer (SMANCS), a conjugate of zinostatin Vorozole (BAN, USAN, rINN) ⊗ tinal disturbances, fatigue, chills, dry mouth and taste disorders. with a styrene-maleic acid polymer, is used for the treatment of Thrombocytopenia and anaemia also occur commonly, and are R-83842; Vorozol; Vorozolum. (+)-6-[4-Chloro-α-(1,2,4-triazol- liver cancer. dose-related; dose reductions may be necessary and in some in- 1-yl)benzyl]-1-methyl-1H-benzotriazole. stances, therapy may need to be stopped. Pulmonary embolism Ворозол has occurred. Other adverse effects include muscle spasms, alo- C16H13ClN6 = 324.8. pecia, dizziness, peripheral oedema, headache, pruritus, cough, CAS — 129731-10-8. Zorubicin Hydrochloride (USAN, rINNM) upper respiratory-tract infection, and pyrexia. Hypokalaemia and ATC — L02BG05. hyperglycaemia have been reported, as has prolongation of the ATC Vet — QL02BG05. Hidrocloruro de zorubicina; NSC-164011; RP-22050 (zoru- QT interval. Blood cell counts, electrolytes, glucose, and serum bicin); Zorubicine, Chlorhydrate de; Zorubicini Hydrochloridum. creatinine should be monitored every 2 weeks during the first 2 Benzoic acid (2S-cis)-{1-[4-(3-amino-2,3,6-trideoxy-α-L-lyxo-hex- months of therapy and monthly thereafter. Baseline and periodic Cl opyranosyloxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-meth- ECG monitoring should be performed. oxy-6,11-dioxonaphthacen-2-yl]ethylidene}hydrazide hydro- Interactions chloride. Severe thrombocytopenia and gastrointestinal bleeding have Зорубицина Гидрохлорид been reported when vorinostat has been given with other histone N deacetylase inhibitors such as valproic acid; platelet counts C34H35N3O10,HCl = 682.1. should be monitored every 2 weeks for the first 2 months of ther- N N CAS — 54083-22-6 (zorubicin); 36508-71-1 (zorubicin apy. Vorinostat may prolong prothrombin time and affect the hydrochloride). H C INR in patients receiving coumarin anticoagulants. 3 ATC — L01DB05. N Pharmacokinetics ATC Vet — QL01DB05. After an oral dose of vorinostat with a high-fat meal, mean time N to maximum plasma concentration was about 4 hours; this was N reduced to 1.5 hours after fasting. Aside from this decrease in the rate of absorption, a high-fat meal also increased the extent of Profile NH2 absorption. While these results were stated not to be clinically Vorozole is a selective nonsteroidal inhibitor of the aromatase HO significant, licensed product information recommends that vori- (oestrogen synthetase) system. It has been investigated in the nostat be taken with food. Plasma protein binding is about 71%. treatment of breast cancer. CH3 H C O OOHO O Vorinostat is metabolised by glucuronidation and hydrolysis fol- ◊ References. 3 lowed by oxidation; metabolites are pharmacologically inactive. H 1. Goss PE, et al. Randomized phase III trial comparing the new N N Less than 1% of a dose is recovered in the urine as unchanged potent and selective third-generation aromatase inhibitor voro- drug. The mean terminal half-life is about 2 hours for vorinostat. zole with megestrol acetate in postmenopausal advanced breast ◊ References. cancer patients. J Clin Oncol 1999; 17: 52–63. O 2. Harper-Wynne CL, et al. Comparison of the systemic and intra- H3C HO 1. Rubin EH, et al. A study to determine the effects of food and tumoral effects of tamoxifen and the aromatase inhibitor voro- OH O multiple dosing on the pharmacokinetics of vorinostat given zole in postmenopausal patients with primary breast cancer. J orally to patients with advanced cancer. Clin Cancer Res 2006; Clin Oncol 2002; 20: 1026–35. 12: 7039–45. (zorubicin) Uses and Administration Vorinostat is a histone deacetylase inhibitor used for the treat- Zinostatin (USAN, rINN) Profile ment of cutaneous T-cell lymphoma (see Non-Hodgkin’s Lym- Zorubicin is an anthracycline antibiotic with antineoplastic ac- Neocarzinostatin; NSC-69856; NSC-157365; Zinostatina; Zi- phomas, p.656). The recommended dose is 400 mg orally, given tions similar to those of doxorubicin (see p.712). It has been used nostatine; Zinostatinum. once daily with food. This may be reduced to 300 mg once daily, as the hydrochloride in the treatment of acute leukaemias. with a further reduction to 300 mg once daily for 5 consecutive Зиностатин days of each week, if needed. Treatment may be continued as CAS — 9014-02-2. 792 Antiparkinsonian Drugs rhoea. There appear to be no important differences in the agement (but see below). However, there is evidence that 18. Katzenschlager R, et al. Anticholinergics for symptomatic man- agement of Parkinson’s disease. Available in The Cochrane Da- efficacy of antimuscarinics for Parkinson’s disease but some patients may benefit from modified-release formula- tabase of Systematic Reviews; Issue 3. Chichester: John Wiley; some patients may tolerate one drug better than another. tions of levodopa with a peripheral dopa-decarboxylase or 2002 (accessed 16/02/06). Those commonly used for Parkinson’s disease include COMT inhibitor. As levodopa competes with amino acids 19. Deane KHO, et al. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Avail- benzatropine, orphenadrine, procyclidine, and trihexy- for uptake into the brain, attempts to lessen fluctuations in able in The Cochrane Database of Systematic Reviews; Issue 4. phenidyl. dopamine brain concentrations have included taking levo- Chichester: John Wiley; 2004 (accessed 16/02/06). 20. Schapira AHV, Olanow CW. Neuroprotection in Parkinson dis- • Amantadine is a weak dopamine agonist with some an- dopa on an empty stomach and also delaying most of a day’s protein consumption until the evening. Addition of ease: mysteries, myths, and misconceptions. JAMA 2004; 291: timuscarinic activity although its activity as an antago- 358–64. entacapone, rasagiline, selegiline, or a dopamine agonist nist of N-methyl-D-aspartate may also have a beneficial 21. Samii A, et al. Parkinson’s disease. Lancet 2004; 363: 1783–93. 22. Thanvi BR, Lo TCN. Long term motor complications of levo- effect in Parkinson’s disease. It has mild antiparkinsoni- may also help to reduce ‘on-off’ phenomena. If fluctua- tions remain a problem subcutaneous apomorphine is of- dopa: clinical features, mechanisms, and management strate- an effects compared with levodopa but is relatively free gies. Postgrad Med J 2004; 80: 452–8. from adverse effects. It can improve bradykinesia as ten effective. In some countries a gel formulation of levo- 23. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology 2004; 62 well as tremor and rigidity but only a small proportion dopa with carbidopa is available for continuous infusion by an ambulatory pump into the duodenum when other (suppl 1): S56–S63. of patients derive much benefit. It is used similarly to 24. Barone P, et al. Treatment of nocturnal disturbances and exces- antimuscarinics in early disease when symptoms are available combination therapy has not been satisfactory. sive daytime sleepiness in Parkinson’s disease. Neurology 2004; Other complications of treatment
Load more

Recommended publications
  • WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT (51) International Patent Classification: A61K 31/53 (2006 .01) A61P 35/00 (2006 .0 1) C07D 251/40 (2006.01) (21) International Application Number: PCT/US20 18/024 134 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,585 24 March 2017 (24.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Devenport Av enue, Berkeley, CA 94619 (US). ANDERSON, Kimberly, E.; 8 Marchant Court, Kensington, CA 94707 (US). (74) Agent: LEE, Joohee et al; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 021 11 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • C19) United States 02) Patent Application Publication (10) Pub
    1111111111111111 IIIIII IIIII 111111111111111 111111111111111 IIIII IIIII IIIII 1111111111 11111111 US 20190241665Al c19) United States 02) Patent Application Publication (10) Pub. No.: US 2019/0241665 Al KREEGER et al. (43) Pub. Date: Aug. 8, 2019 (54) METHODS OF INHIBITING METASTASIS IN C07K 16/24 (2006.01) CANCER C12N 15/113 (2006.01) A61K 31/439 (2006.01) (71) Applicant: WISCONSIN ALUMNI RESEARCH (52) U.S. Cl. FOUNDATION, Madison, WI (US) CPC .......... C07K 1612854 (2013.01); A61P 35/04 (2018.01); C07K 16/24 (2013.01); Cl2N (72) Inventors: PAMELA KAY KREEGER, 2310/14 (2013.01); C12N 15/1138 (2013.01); MIDDLETON, WI (US); MOLLY A61K 31/439 (2013.01); C07K 2317/76 JANE CARROLL, MADISON, WI (2013.01); C07K 16/2866 (2013.01) (US); KAITLIN C. FOGG, FITCHBURG, WI (US) (57) ABSTRACT (21) Appl. No.: 16/256,065 As described herein, a method of inhibiting metastasis in (22) Filed: Jan. 24, 2019 cancer includes administering to a human subject diagnosed with a cancer of an organ of the peritoneal cavity a thera­ Related U.S. Application Data peutically effective amount of an inhibitor of CCR5 or P-selectin. Preferably the subject has a tumor positive for a (60) Provisional application No. 62/621,769, filed on Jan. ligand of P-selectin such as a CD24+ or PSGL-1 + tumor. 25, 2018. Analysis of samples from HGSOC patients confirmed increased MIP-1 fJ and P-selectin, suggesting that this novel Publication Classification multi-cellular mechanism can be targeted to slow or stop (51) Int. Cl. metastasis in cancers such as high-grade serous ovarian C07K 16/28 (2006.01) cancer, for example by using anti-CCR5 and P-selectin A61P 35/04 (2006.01) therapies developed for other indications.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,716.252 B2 Schafer Et Al
    US008716252B2 (12) United States Patent (10) Patent No.: US 8,716.252 B2 Schafer et al. (45) Date of Patent: May 6, 2014 (54) (METHYLSULFONYL) ETHYL BENZENE (51) Int. Cl. ISONDOLINEDERVATIVES AND THEIR A613 L/70 (2006.01) PHARMACEUTICALUSES A613 L/40 (2006.01) C07H 17/02 (2006.01) (75) Inventors: Peter H. Schafer, Somerset, NJ (US); C07D 209/16 (2006.01) Anthony J. Frank, Easton, PA (US); (52) U.S. Cl. Hon-Wah Man, Princeton, NJ (US); Sai USPC ............. 514/27: 514/416:536/17.4: 548/472 L. Shankar, Chesterfield, NJ (US) (58) Field of Classification Search None (73) Assignee: Celgene Corporation, Summit, NJ (US) See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 0 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 13/518,843 6,667,316 B1* 12/2003 Man et al. ..................... 514,323 (22) PCT Filed: Dec. 21, 2010 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O10/06142O WO WOO1,34606 5, 2001 S371 (c)(1), * cited by examiner (2), (4) Date: Aug. 21, 2012 Primary Examiner — Traviss C McIntosh, III (87) PCT Pub. No.: WO2011/079091 (74) Attorney, Agent, or Firm — Jones Day PCT Pub. Date: Jun. 30, 2011 (57) ABSTRACT (65) Prior Publication Data Provided are (methylsulfonyl)ethyl benzene isoindoline US 2013/O1162O4 A1 May 9, 2013 compounds, and pharmaceutically acceptable salts, Solvates, O O or stereoisomers thereof. Methods of use and pharmaceutical Related U.S. Application Data compositions of these compounds are also disclosed.
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • WO 2014/114801 Al 31 July 2014 (31.07.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/114801 Al 31 July 2014 (31.07.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) A61K 47/48 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/30 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 14/05 155 1 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 27 January 2014 (27.01 .2014) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, zw. (30) Priority Data: 61/756,977 25 January 2013 (25.01.2013) US (84) Designated States (unless otherwise indicated, for every 61/785,1 19 14 March 2013 (14.03.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: AMGEN INC.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,107,824 B2 Pilkiewicz Et Al
    US009 107824B2 (12) United States Patent (10) Patent No.: US 9,107,824 B2 Pilkiewicz et al. (45) Date of Patent: Aug. 18, 2015 (54) METHODS OF TREATING CANCER WITH (58) Field of Classification Search HIGH POTENCY LIPID-BASED PLATINUM None COMPOUND FORMULATIONS See application file for complete search history. ADMINISTERED INTRAPERITONEALLY (75) Inventors: Frank G. Pilkiewicz, Princeton (56) References Cited Junction, NJ (US); Roman Perez-Soler, New York, NY (US): Yiyu Zou, Bronx, U.S. PATENT DOCUMENTS NY (US); Walter R. Perkins, 3,993,754 A 11/1976 Rahman et al. Pennington, NJ (US); Jin K. Lee, Belle 8/1978 Lundquist Mead, NJ (US); Vladimir Malinin, 4,105,027 A Plainsboro, NJ (US) (Continued) (73) Assignee: Insmed Incorporated, Bridgewater, NJ FOREIGN PATENT DOCUMENTS (US) (*) Notice: Subject to any disclaimer, the term of this CN 1088777 T 1994 patent is extended or adjusted under 35 EP O551169 7, 1993 U.S.C. 154(b) by 1194 days. (Continued) (21) Appl. No.: 12/122,191 OTHER PUBLICATIONS (22) Filed: May 16, 2008 Office Action for Australian ApplicationNo. 2003302314, dated May (Under 37 CFR 1.47) 26, 2008, 2 pages. (Continued) (65) Prior Publication Data US 2009/O 130193 A1 May 21, 2009 Primary Examiner — Bethany Barham Related U.S. Application Data Assistant Examiner — Barbara Frazier (63) Continuation-in-part of application No. 1 1/592,754, (74) Attorney, Agent, or Firm — Cooley LLP filed on Nov. 3, 2006, now abandoned. (60) Provisional application No. 60/734,474, filed on Nov. (57) ABSTRACT 8, 2005. One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperito (51) Int.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0222392 A1
    0001US 20200222392A1 IN (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0222392 A1 Pollard et al. (43 ) Pub . Date : Jul. 16 , 2020 (54 ) COMPOUNDS USEFUL AS INHIBITORS OF (52 ) U.S. CI. ATR KINASE AND COMBINATION CPC A61K 31/496 ( 2013.01) ; A61K 31/4965 THERAPIES THEREOF (2013.01 ) ; A61K 31/497 ( 2013.01) ; C07D 413/04 ( 2013.01 ) ; A61K 33/24 ( 2013.01 ) ; (71 ) Applicant: Vertex Pharmaceuticals Incorporated , A61K 45/06 ( 2013.01) ; A61K 31/55 ( 2013.01) Boston , MA (US ) (57 ) ABSTRACT The present invention relates to compounds useful as inhibi ( 72 ) Inventors : John Robert Pollard , Abingdon (GB ) ; tors of ATR protein kinase and combination therapies Philip Michael Reaper, Abingdon thereof The invention also relates to pharmaceutically (GB ) ; Mohammed Asmal, Newton , acceptable compositions comprising the compounds of this MA (US ) invention ;methods of treating of various diseases, disorders , and conditions using the compounds of this invention ; ( 21) Appl. No .: 16 /507,139 processes for preparing the compounds of this invention ; intermediates for the preparation of the compounds of this ( 22 ) Filed : Jul. 10 , 2019 invention ; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and Related U.S. Application Data pathological phenomena ; the study of intracellular signal (60 ) Continuation of application No. 14 / 816,432 , filed on transduction pathways mediated by such kinases ; and the Aug. 3 , 2015 , now Pat . No. 10,478,430 , which is a comparative evaluation of new kinase inhibitors. division of application No. 13 /857,658 , filed on Apr. The compounds of this invention have formula I: 5 , 2013 , now abandoned .
    [Show full text]
  • Electronic Supplementary Material (ESI) for RSC Advances. This Journal Is © the Royal Society of Chemistry 2016
    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2016 Quantum-chemically-calculated mechanistically interpretable molecular descriptors for drug-action mechanism study – a case study of anthracycline anticancer antibiotics Siu-Kwong Pang Institute of Textiles and Clothing, Faculty of Applied Science and Textiles, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. Email: [email protected] Tel.: +852 94965619 Supplementary Information Page 1 of 242 1. Log GI50 (60 cell lines) for anthracyclines Experiment 1 Experiment 2 Experiment 3 Experiment 4 Experiment 5 Log Log Log(Hig Log(Hig Log(Hig (Highest (Highest hest hest hest concentr concentr concentr concentr concentr average span of NSC No. / Log ation of Log ation of Log ation of Log ation of Log ation of Name Log GI (M) GI (M) GI (M) GI (M) GI (M) log CAS No. 50 (GI ) drugs 50 (GI ) drugs 50 (GI ) drugs 50 (GI ) drugs 50 (GI ) drugs (GI ) 50 50 50 50 50 (GI ) 50 for for for for for 50 experim experim experim experim experim ents) ents) ents) ents) ents) 3'-Acetoxy-4'-O- 3.81E- 73113-92-5 -6.419 -6.419 -4.0 acetyldoxorubicin 07 1.60E- Aclacinomycin X NSC 670120 -7.796 -7.796 -5.0 08 5.85E- Aclarubicin 57576-44-0 -8.233 -8.233 -5.0 09 Adriamycin 14- 7.60E- 51898-39-6 -7.119 -7.119 -4.0 octanoate 08 1.99E- Aklavin 60504-57-6 -6.701 -6.701 -4.0 07 2'-Bromo-4'-epi- 4.02E- 5.43E- NSC 650931 -7.330 -7.396 -4.0 -7.265 -5.0 0.131 daunorubicin 08 08 NSC 243022 1.49E- Cinerubin A -9.827 -9.827 -7.0 / 34044-10-5 10 N-(1-Cyano-2-
    [Show full text]
  • (12) United States Patent (1O) Patent No.: US 8,173,115 B2 Decuzzi Et Al
    (12) United States Patent (1o) Patent No.: US 8,173,115 B2 Decuzzi et al. (45) Date of Patent: *May 8, 2012 (54) PARTICLE COMPOSITIONS WITH A OTHER PUBLICATIONS PRE-SELECTED CELL INTERNALIZATION International Search Report and Written Opinion mailed Jun. 3, MODE 2009, in PCT/US2008/071470, 15 pages. (75) Inventors: Paolo Decuzzi, Bari (IT); Mauro U.S. Appl. No. 12/110,515, filed Apr. 28, 2008, Ferrari et al. Ferrari, Houston, TX (US) Champion et al., "Making polymeric micro- and nanoparticles of complex shapes," PHAS, Jul. 17, 2007, 104(29):11901-11904. (73) Assignee: The Board of Regents of The Champion et al., "Role of target geometry in phagocytosis," PHAS, University of Texas System, Austin, TX Mar. 28, 2006, 103(13):4930-4934. Cohen et al., "Microfabrication of Silicon-Based Nanoporous Par- (US) ticulates for Medical Applications," Biomedical Microdevices, 2003, 5(3):253-259. (*) Notice: Subject to any disclaimer, the term of this Conner et al., "Regulated portals of entry into the cell," Nature, Mar. patent is extended or adjusted under 35 6, 2003, 422:37-44. U.S.C. 154(b) by 390 days. Decuzzi et al,. "The role of specific and non-specific interactions in This patent is subject to a terminal dis- receptor-mediated endocytosis of nanoparticles," Biomaterials, claimer. 2007, 28:2915-2922. Decuzzi et al., "A Theoretical Model for the Margination of Particles (21) Appl. No.: 12/181,759 within Blood Vessels," Annals of Biomedical Engineering, Feb. 2005, 33(2):179-190. (22) Filed: Jul. 29, 2008 Decuzzi et al., "Adhesion of Microfabricated Particles of Vascular Endothelium: A Parametric Analysis," Annals of Biomedical Engi- (65) Prior Publication Data neering, Jun.
    [Show full text]